10 analysts have shared their evaluations of Labcorp Hldgs LH throughout the latest three months, expressing a mixture of bullish and bearish views.
The desk under summarizes their latest rankings, showcasing the evolving sentiments inside the previous 30 days and evaluating them to the previous months.
| Bullish | Considerably Bullish | Detached | Considerably Bearish | Bearish | |
|---|---|---|---|---|---|
| Whole Scores | 5 | 2 | 3 | 0 | 0 |
| Final 30D | 1 | 0 | 0 | 0 | 0 |
| 1M In the past | 1 | 0 | 3 | 0 | 0 |
| 2M In the past | 1 | 1 | 0 | 0 | 0 |
| 3M In the past | 2 | 1 | 0 | 0 | 0 |
The 12-month value targets, analyzed by analysts, provide insights with a median goal of $274.8, a excessive estimate of $300.00, and a low estimate of $260.00. Witnessing a optimistic shift, the present common has risen by 4.8% from the earlier common value goal of $262.22.
Decoding Analyst Scores: A Nearer Look
An in-depth evaluation of latest analyst actions unveils how monetary consultants understand Labcorp Hldgs. The next abstract outlines key analysts, their latest evaluations, and changes to rankings and value targets.
| Analyst | Analyst Agency | Motion Taken | Ranking | Present Value Goal | Prior Value Goal |
|---|---|---|---|---|---|
| Ralph Giacobbe | Citigroup | Raises | Purchase | $300.00 | $250.00 |
| David Westenberg | Piper Sandler | Raises | Impartial | $260.00 | $240.00 |
| Jack Meehan | Barclays | Lowers | Equal-Weight | $260.00 | $271.00 |
| Tycho Peterson | Jefferies | Raises | Purchase | $290.00 | $275.00 |
| Jack Meehan | Barclays | Raises | Equal-Weight | $271.00 | $249.00 |
| Kevin Caliendo | UBS | Lowers | Purchase | $286.00 | $293.00 |
| Elizabeth Anderson | Evercore ISI Group | Raises | Outperform | $265.00 | $260.00 |
| Ricky Goldwasser | Morgan Stanley | Raises | Obese | $270.00 | $260.00 |
| Derik De Bruin | B of A Securities | Raises | Purchase | $271.00 | $262.00 |
| Tycho Peterson | Jefferies | Broadcasts | Purchase | $275.00 | – |
Key Insights:
- Motion Taken: In response to dynamic market situations and firm efficiency, analysts replace their suggestions. Whether or not they ‘Preserve’, ‘Elevate’, or ‘Decrease’ their stance, it signifies their response to latest developments associated to Labcorp Hldgs. This perception provides a snapshot of analysts’ views on the present state of the corporate.
- Ranking: Analyzing traits, analysts provide qualitative evaluations, starting from ‘Outperform’ to ‘Underperform’. These rankings convey expectations for the relative efficiency of Labcorp Hldgs in comparison with the broader market.
- Value Targets: Analysts present insights into value targets, providing estimates for the long run worth of Labcorp Hldgs’s inventory. This comparability reveals traits in analysts’ expectations over time.
Navigating by means of these analyst evaluations alongside different monetary indicators can contribute to a holistic understanding of Labcorp Hldgs’s market standing. Keep knowledgeable and make data-driven selections with our Scores Desk.
Keep updated on Labcorp Hldgs analyst rankings.
About Labcorp Hldgs
Labcorp is among the nation’s two largest impartial medical laboratories, with roughly 20% of the impartial lab market. The corporate operates roughly 2,000 patient-service facilities, providing a broad vary of 5,000 medical lab checks, starting from routine blood and urine screens to complicated oncology and genomic testing.
Monetary Insights: Labcorp Hldgs
Market Capitalization: Boasting an elevated market capitalization, the corporate surpasses trade averages. This indicators substantial dimension and powerful market recognition.
Income Development: Labcorp Hldgs’s income development over a interval of three months has been noteworthy. As of 31 December, 2024, the corporate achieved a income development charge of roughly 9.76%. This means a considerable enhance within the firm’s top-line earnings. As in comparison with opponents, the corporate encountered difficulties, with a development charge decrease than the typical amongst friends within the Well being Care sector.
Web Margin: Labcorp Hldgs’s internet margin surpasses trade requirements, highlighting the corporate’s distinctive monetary efficiency. With a powerful 4.31% internet margin, the corporate successfully manages prices and achieves sturdy profitability.
Return on Fairness (ROE): The corporate’s ROE is under trade benchmarks, signaling potential difficulties in effectively utilizing fairness capital. With an ROE of 1.77%, the corporate may have to handle challenges in producing passable returns for shareholders.
Return on Property (ROA): Labcorp Hldgs’s ROA surpasses trade requirements, highlighting the corporate’s distinctive monetary efficiency. With a powerful 0.78% ROA, the corporate successfully makes use of its property for optimum returns.
Debt Administration: With a below-average debt-to-equity ratio of 0.9, Labcorp Hldgs adopts a prudent monetary technique, indicating a balanced method to debt administration.
Analyst Scores: What Are They?
Analysts work in banking and monetary programs and usually concentrate on reporting for shares or outlined sectors. Analysts could attend firm convention calls and conferences, analysis firm monetary statements, and talk with insiders to publish “analyst rankings” for shares. Analysts usually charge every inventory as soon as per quarter.
Some analysts publish their predictions for metrics akin to development estimates, earnings, and income to supply further steerage with their rankings. When utilizing analyst rankings, you will need to remember the fact that inventory and sector analysts are additionally human and are solely providing their opinions to traders.
If you wish to maintain observe of which analysts are outperforming others, you’ll be able to view up to date analyst rankings alongside withanalyst success scores in Benzinga Professional.
Breaking: Wall Avenue’s Subsequent Huge Mover
Benzinga’s #1 analyst simply recognized a inventory poised for explosive development. This under-the-radar firm may surge 200%+ as main market shifts unfold. Click on right here for pressing particulars.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
